573 results about "Nanocarriers" patented technology

The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides vaccine nanocarriers capable of stimulating an immune response in T cells and/or in B cells, in some embodiments, comprising at least one immunomodulatory agent, and optionally comprising at least one targeting moiety and optionally at least one immunostimulatory agent. The invention provides pharmaceutical compositions comprising inventive vaccine nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive vaccine nanocarriers and pharmaceutical compositions thereof. The invention provides methods of prophylaxis and/or treatment of diseases, disorders, and conditions comprising administering at least one inventive vaccine nanocarrier to a subject in need thereof.

This invention relates, in part, to methods of using emulsions for making synthetic nanocarriers and the synthetic nanocarriers formed by such methods.

This invention relates to compositions, and related methods, of synthetic nanocarriers that comprise immunomodulatory agents and antigens that are differentially released from the synthetic nanocarriers.

This invention relates, at least in part, to osmotic mediated release barrier-free synthetic nanocarriers and methods of production and use.

Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically acceptable excipient.

Disclosed are synthetic nanocarrier compositions with separate adjuvant compositions as well as related methods.

The invention provides new compositions and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide/microcarrier (IMP/MC) complexes. The IMP/MC complexes may be covalently or non-covalently bound, and feature a polynucleotide comprising at least one immunostimulatory sequence bound to a nonbiodegradable microcarrier or nanocarrier.

Disclosed are synthetic nanocarrier compositions, and related methods, comprising therapeutic protein APC presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to therapeutic proteins.

A method of tuning the size of an nano-active material on a nano-carrier material comprising: providing a starting portion of a carrier material and a starting portion of an active material in a first ratio; adjusting the first ratio, forming a second ratio, thereby tuning the ratio of active material and carrier material; combining the portion of the active material in a vapor phase and the portion of the carrier material in a vapor phase, forming a conglomerate in a vapor phase; and changing the phase of the conglomerate, thereby forming nano-spheres comprising a nano-carrier material decorated with a nano-active material, wherein the size of the nano-active material is dependent upon the second ratio.

Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering immunosuppressants and MHC Class I-restricted and/or MHC Class II-restricted epitopes that can generate tolerogenic immune responses (e.g., antigen-specific T effector cell deletion).

Disclosed are synthetic nanocarrier compositions, and related methods, comprising APC presentable transplant antigens and immunosuppressants that provide tolerogenic immune responses (e.g., a reduction in CD8+ T cell proliferation and/or activity) specific to the APC presentable transplant antigens.

Disclosed are synthetic nanocarrier compositions that comprise B cell antigen for desired antibody production and an off-target response attenuating polymeric coating as well as related methods.

Targeted therapeutic delivery systems comprising specially-designed nanocarriers for intracellular therapeutic delivery, mediated by acoustic energy, for use either in vivo or in vitro are detailed. Nanocarriers comprised substantially of dendritic biopolymers and other species and compounds; are used to treat a variety of diseases in humans and other species, such as cancer, opthalmological, pulmonary, urinary or other pathologies. Methods for preparing the targeted therapeutic delivery systems are also embodied, which comprise processing a solution comprising biopolymers or other species and components, with or without targeting moieties, adding said biopolymers and other compounds to a solution containing one or more therapeutic agents, stabilizing or not stabilizing said nanocarriers, adding one or more contrast agents, resulting in a targeted therapeutic delivery system. Preferred therapeutics for use with the present invention include nucleic acids, proteins, peptides, and other therapeutic macromolecules.

A two-step targeted tumor therapeutic method is described comprising nanocarrier with prodrug encapsulated thereto and prodrug activating enzyme. The enzyme is either encapsulated in nanocarrier, or not encapsulated, or synthesized in the tumor. With the method, the prodrug released from the nanocarrier is activated by the enzyme mainly in the tumor.

Disclosed are synthetic nanocarrier compositions and immune checkpoint inhibitor compositions and related methods for administration to a subject.

Disclosed is a surfacely modified hydrophobic Chitosan oligosaccharide polymer drug-loaded colloidal cluster, obtained by grafting chitosan with a average molecular weight of 1.5kD-51kD and aliphatic acid of C10-C22, comprising based on hydrophobic modified Chitosan oligosaccharide polimer colloidal clusters, modifying amidogens or hydroxy groups of Chitosan oligosaccharide molecules on polimer surface with bi-functional small organic moleculers, forming chemical bond bridges between molecules on the surfaces of polymer colloidal clusters,to improve the instability of polymer colloidal cluster diluted, and to imorove the original loose structure of polimer colloidal cluster surfece to form a fine and close net-shaped structure, to decrease a sudden release of drugs, and to control drugs with slow release. The drug-loaded colloidal cluster provided is a nano-carrier with excellent organelle targeting, is applicated in life science field and pharmacy field.

Disclosed herein are nanoparticle, micelle and/or liposome compositions, each comprising a therapeutic agent encapsulated in one or more polymer(s), wherein a vitamin B12 or a derivative thereof is attached to the one or more polymer(s) via a linker group, as well as methods for making and using same.

The invention provides a magnetic nanomaterial-mediated CRISPR/Cas9 T-cell internal delivery system and a preparation method and the application thereof. The preparation method comprises the followingsteps: 1) modifying a magnetic nanoparticle cluster with a certain size by using a cationic polymer to obtain a nanocarrier; 2) providing CRISPR/Cas9 system expression plasmids targeting a target gene; 3) co-incubating the nanocarrier obtained in the step 1) and the CRISPR/Cas9 system expression plasmids targeting the target gene to obtain a nanocomposite; 4) under the action of a magnetic field,co-incubating the nanocomposite obtained in the step 3) and a T cell to obtain the magnetic nanomaterial-mediated CRISPR/Cas9 T-cell internal delivery system. According to the invention, a method capable of simply, safely and efficiently editing the target gene in the T cell is provided; the magnetic nanomaterial-mediated CRISPR/Cas9 T-cell internal delivery system has a good application prospectin tumor immunotherapy.